Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin dose and induction-cycle randomization in adults with newly diagnosed AML
2013-003191-12Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin in acute myeloid leukemia (AML) (4 arms), sponsored by Technische Universität Dresden. Primary endpoint: Rate of good responders at day 15. Started Nov 2013; status: completed.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2013-003191-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003191-12.